CL2018001978A1 - Inactivación de patógenos por delipidación - Google Patents
Inactivación de patógenos por delipidaciónInfo
- Publication number
- CL2018001978A1 CL2018001978A1 CL2018001978A CL2018001978A CL2018001978A1 CL 2018001978 A1 CL2018001978 A1 CL 2018001978A1 CL 2018001978 A CL2018001978 A CL 2018001978A CL 2018001978 A CL2018001978 A CL 2018001978A CL 2018001978 A1 CL2018001978 A1 CL 2018001978A1
- Authority
- CL
- Chile
- Prior art keywords
- viruses
- mbcd
- delipidation
- virus
- encapsulated
- Prior art date
Links
- 230000015961 delipidation Effects 0.000 title abstract 3
- 230000002779 inactivation Effects 0.000 title 1
- 244000052769 pathogen Species 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 235000012000 cholesterol Nutrition 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- -1 CHOLESTEROL Chemical class 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- PIGWQFXBEUEJSB-UHFFFAOYSA-N s-[2-(diethylamino)ethyl] pyridine-3-carbothioate Chemical compound CCN(CC)CCSC(=O)C1=CC=CN=C1 PIGWQFXBEUEJSB-UHFFFAOYSA-N 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10051—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A VACUNAS QUE CONTIENEN VIRUS ENCAPSULADOS CUYAS ENVOLTURAS HAN REDUCIDO SU NÚMERO DE LÍPIDOS USANDO ß-CICLODEXTRINA DE METILO (MBCD). LA DELIPIDACIÓN DE VIRUS ENCAPSULADOS EN UN PROCESO DE DOS PASOS ELIMINA LA INFECTIVIDAD DE ESOS VIRUS, LO QUE PERMITE QUE LOS VIRUS DELIPIDADOS SE UTILICEN DE FORMA SEGURA EN LAS VACUNAS. EL USO DE MBCD PARA ELIMINAR LOS LÍPIDOS TALES COMO EL COLESTEROL, EN CONTRASTE CON OTROS MÉTODOS, DA COMO RESULTADO UN VIRUS CON MENOS DE 20% DEL COLESTEROL DE UN VIRUS NO TRATADO, PERO TALES VIRUS DELIPIDADOS CONSERVAN AL MENOS 85% DEL CONTENIDO DE PROTEÍNAS DE UN VIRUS NO TRATADO. LA DELIPIDACIÓN POR MBCD TAMBIÉN PRESERVA LA INMUNOGENICIDAD DE LAS PROTEÍNAS VÍRICAS. LA PRESENTE INVENCIÓN DEL USO DEL TRATAMIENTO MBCD EN UN PROCESO DE DOS ETAPAS PARA DESLIPIDAR VIRUS ENCAPSULADOS REPRESENTA UNA NUEVA ALTERNATIVA PARA LA GENERACIÓN DE VIRUS INACTIVADOS QUE SE INCORPORAN EN VACUNAS EFICACES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662287488P | 2016-01-27 | 2016-01-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018001978A1 true CL2018001978A1 (es) | 2018-10-26 |
Family
ID=57915178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018001978A CL2018001978A1 (es) | 2016-01-27 | 2018-07-20 | Inactivación de patógenos por delipidación |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10420831B2 (es) |
| EP (1) | EP3408280B1 (es) |
| JP (1) | JP6648286B2 (es) |
| KR (1) | KR102202475B1 (es) |
| CN (1) | CN108602860B (es) |
| AR (1) | AR107262A1 (es) |
| AU (1) | AU2017211040B2 (es) |
| CA (1) | CA3008965C (es) |
| CL (1) | CL2018001978A1 (es) |
| DK (1) | DK3408280T3 (es) |
| EA (1) | EA038712B1 (es) |
| ES (1) | ES2839623T3 (es) |
| MX (1) | MX2018008365A (es) |
| NZ (1) | NZ743601A (es) |
| PL (1) | PL3408280T3 (es) |
| TW (1) | TWI747866B (es) |
| WO (1) | WO2017132059A1 (es) |
| ZA (1) | ZA201804025B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12226431B2 (en) | 2021-09-11 | 2025-02-18 | Porosome Therapeutics, Inc. | Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses |
| EP4678649A1 (en) * | 2024-07-10 | 2026-01-14 | Roquette Freres | Use of substituted cyclodextrin for viral inactivation in biomanufacturing |
| WO2026013232A1 (en) * | 2024-07-10 | 2026-01-15 | Roquette Freres | Use of substituted cyclodextrin for viral inactivation in biomanufacturing |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2243994T5 (es) * | 1996-04-19 | 2009-10-29 | Grifols Inc. | Procedimiento para la inactivacion virica de proteinas de la sangre liofilizadas. |
| ZA988446B (en) | 1997-09-18 | 2000-03-22 | Res Dev Foundation | Production of vaccines using arthropod vectored viruses. |
| AUPQ846900A0 (en) | 2000-06-29 | 2000-07-27 | Aruba International Pty Ltd | A vaccine |
| US7407662B2 (en) | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified viral particles with immunogenic properties and reduced lipid content |
| US20090017069A1 (en) * | 2000-06-29 | 2009-01-15 | Lipid Sciences, Inc. | SARS Vaccine Compositions and Methods of Making and Using Them |
| CU23002A1 (es) | 2000-12-01 | 2004-11-18 | Ct Ingenieria Genetica Biotech | Método de obtención de agregados antigénicos y su uso en formulaciones |
| US8613934B2 (en) | 2004-03-22 | 2013-12-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cellular and viral inactivation |
| JP2006328039A (ja) * | 2005-04-26 | 2006-12-07 | Nippo Kagaku Kk | 鳥インフルエンザウイルス不活化剤 |
| WO2009014774A1 (en) * | 2007-04-06 | 2009-01-29 | Inviragen, Inc. | Methods and compositions for live attenuated viruses |
| GB0720503D0 (en) | 2007-10-22 | 2007-11-28 | Angeletti P Ist Richerche Bio | New compound |
| EP2062594A1 (en) * | 2007-11-21 | 2009-05-27 | Wyeth Farma, S.A. | Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same |
| CA2871786C (en) * | 2012-04-24 | 2021-11-16 | Ohio State Innovation Foundation | Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome |
-
2016
- 2016-12-29 AR ARP160104075A patent/AR107262A1/es active IP Right Grant
- 2016-12-30 TW TW105144117A patent/TWI747866B/zh not_active IP Right Cessation
-
2017
- 2017-01-20 EA EA201891371A patent/EA038712B1/ru unknown
- 2017-01-20 CA CA3008965A patent/CA3008965C/en active Active
- 2017-01-20 MX MX2018008365A patent/MX2018008365A/es unknown
- 2017-01-20 JP JP2018539364A patent/JP6648286B2/ja active Active
- 2017-01-20 DK DK17702277.9T patent/DK3408280T3/da active
- 2017-01-20 US US16/060,561 patent/US10420831B2/en active Active
- 2017-01-20 NZ NZ743601A patent/NZ743601A/en unknown
- 2017-01-20 AU AU2017211040A patent/AU2017211040B2/en active Active
- 2017-01-20 WO PCT/US2017/014267 patent/WO2017132059A1/en not_active Ceased
- 2017-01-20 ES ES17702277T patent/ES2839623T3/es active Active
- 2017-01-20 CN CN201780008323.7A patent/CN108602860B/zh active Active
- 2017-01-20 KR KR1020187021286A patent/KR102202475B1/ko active Active
- 2017-01-20 PL PL17702277T patent/PL3408280T3/pl unknown
- 2017-01-20 EP EP17702277.9A patent/EP3408280B1/en active Active
-
2018
- 2018-06-15 ZA ZA2018/04025A patent/ZA201804025B/en unknown
- 2018-07-20 CL CL2018001978A patent/CL2018001978A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180096775A (ko) | 2018-08-29 |
| JP2019506860A (ja) | 2019-03-14 |
| DK3408280T3 (da) | 2021-01-04 |
| CN108602860A (zh) | 2018-09-28 |
| CN108602860B (zh) | 2023-05-26 |
| EA201891371A1 (ru) | 2019-01-31 |
| KR102202475B1 (ko) | 2021-01-12 |
| JP6648286B2 (ja) | 2020-02-14 |
| ES2839623T3 (es) | 2021-07-05 |
| AU2017211040B2 (en) | 2020-10-08 |
| WO2017132059A1 (en) | 2017-08-03 |
| CA3008965A1 (en) | 2017-08-03 |
| BR112018014542A2 (pt) | 2018-12-11 |
| EP3408280A1 (en) | 2018-12-05 |
| TW201733615A (zh) | 2017-10-01 |
| AR107262A1 (es) | 2018-04-11 |
| TWI747866B (zh) | 2021-12-01 |
| US20180360945A1 (en) | 2018-12-20 |
| NZ743601A (en) | 2020-03-27 |
| ZA201804025B (en) | 2020-08-26 |
| AU2017211040A1 (en) | 2018-06-28 |
| CA3008965C (en) | 2021-04-13 |
| MX2018008365A (es) | 2018-09-17 |
| EP3408280B1 (en) | 2020-11-25 |
| PL3408280T3 (pl) | 2021-05-31 |
| US10420831B2 (en) | 2019-09-24 |
| EA038712B1 (ru) | 2021-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2018000074A (es) | Moduladores de la proteína core de la hepatitis b | |
| MX2018007198A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
| AR133161A2 (es) | Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos | |
| ECSP14013315A (es) | Inhibidores de aplicación viral | |
| EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
| MX347210B (es) | Vacunas combinadas para prevención de infecciones por virus porcino. | |
| CU20180025A7 (es) | Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue | |
| BR112018012642A2 (pt) | vacina de calicivírus felino | |
| AR101814A1 (es) | Partícula de tipo virus flavivirus | |
| CO2018010874A2 (es) | Vacuna de virus de zika atenuado vivo | |
| CU24580B1 (es) | Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas | |
| CL2018001978A1 (es) | Inactivación de patógenos por delipidación | |
| ECSP18081582A (es) | Constructos de alfavirus vivo atenuado y métodos y usos de los mismos | |
| CL2021003211A1 (es) | Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018) | |
| PE20160596A1 (es) | Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana | |
| AU2017261705A1 (en) | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | |
| UY35418A (es) | Vacuna que proporciona protección frente a diferentes Picornavirus humanos. | |
| MX2019009810A (es) | Formas cristalinas de cabotegravir de sodio. | |
| MX2018006500A (es) | Virus vivo que tiene un banco de cepas atenuadas del virus del dengue, y una vacuna contra el dengue que contiene el mismo como antigenos. | |
| AR094912A1 (es) | Vacuna contra el virus de la leucemia bovina | |
| EA202191862A3 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
| AR107093A1 (es) | Composiciones inmunogénicas | |
| EA201792083A1 (ru) | Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний | |
| NI201400025A (es) | Inhibidores de aplicación viral | |
| EA201691835A1 (ru) | Аллостерические модуляторы капсидного белка гепатита в |